Qarziba Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of high-risk neuroblastoma, advancements in monoclonal antibody development, expansion of pediatric oncology treatment centers, improved survival outcomes with immunotherapy, regulatory approvals for targeted cancer therapies.

The growth in the forecast period can be attributed to expansion of precision oncology research, rising adoption of GD2-targeted therapies, increasing investments in pediatric cancer immunotherapy, growing focus on personalized treatment protocols, expansion of global access to advanced oncology drugs. Major trends in the forecast period include expansion of targeted immunotherapy adoption, growing use of monoclonal antibodies in pediatric oncology, increasing focus on relapse prevention therapies, rising integration of immunotherapy in multimodal treatment regimens, enhanced clinical monitoring of treatment outcomes.

The rising prevalence of cancer is expected to support the expansion of the qarziba market in the coming years. The increase in cancer cases is linked to factors such as an aging population, lifestyle-related risks including smoking, unhealthy diets, physical inactivity, and genetic susceptibility. Qarziba (dinutuximab beta) is used in pediatric oncology for the treatment of high-risk neuroblastoma by targeting GD2-expressing cancer cells, strengthening immune-mediated tumor destruction, and lowering the risk of relapse in this aggressive cancer type. For instance, in August 2024, according to a report released by the Australian Institute of Health and Welfare, an Australian government agency responsible for national health and welfare statistics, Australia is projected to record approximately 209,000 new cancer cases by 2034, up from an estimated 169,000 diagnoses anticipated in 2024, highlighting the impact of population growth and increasing cancer incidence. Therefore, the increasing prevalence of cancer is expected to drive the growth of the qarziba market.

Leading companies operating in the Qarziba market are increasingly adopting strategic partnership strategies to strengthen technology integration and broaden their market presence. Strategic partnerships generally involve collaborative agreements in which organizations pool resources, expertise, and capabilities to achieve shared objectives. For example, in July 2024, Farma Mondo Hong Kong Ltd., a Hong Kong-based subsidiary of the Switzerland-based Farma Mondo Group that focuses on market access and specialty pharmaceutical distribution, entered into an exclusive licensing and distribution agreement with Recordati UK Ltd. for Qarziba (dinutuximab beta) in Hong Kong. Through this agreement, Farma Mondo Hong Kong became the local marketing authorization holder and assumed responsibility for the commercial distribution of the neuroblastoma therapy within the region. Recordati UK Ltd. is a pharmaceutical company based in the United Kingdom.

In July 2024, Farma Mondo Hong Kong Ltd., a China-based pharmaceutical company, entered into a partnership with Recordati UK Ltd. to distribute Qarziba in Hong Kong. Under the terms of this collaboration, Farma Mondo will act as the local Marketing Authorization Holder (MAH), managing the commercial distribution of Qarziba, a treatment used for high-risk neuroblastoma that primarily affects children under the age of five. Recordati UK Ltd. is a UK-based pharmaceutical company.

Major companies operating in the qarziba market are EUSA Pharma (UK) Ltd.

North America was the largest region in the qarziba market in 2025. The regions covered in the qarziba market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the qarziba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the qarziba market by increasing costs of imported biologic raw materials, active pharmaceutical ingredients, cold-chain packaging systems, and specialized manufacturing equipment used in monoclonal antibody production. European and North American markets are most affected due to reliance on cross-border biologics supply chains and specialized production inputs. These tariffs are increasing production and distribution costs and placing pressure on pricing strategies for hospital-administered therapies. However, they are also encouraging localized biologics manufacturing, regional supply chain strengthening, and long-term investments in domestic immunotherapy production capacity.

The qarziba market research report is one of a series of new reports that provides qarziba market statistics, including qarziba industry global market size, regional shares, competitors with a qarziba market share, detailed qarziba market segments, market trends and opportunities, and any further data you may need to thrive in the qarziba industry. This qarziba market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Qarziba (dinutuximab beta) is a monoclonal antibody therapy used in the treatment of high-risk neuroblastoma in pediatric patients. It targets the GD2 antigen present on neuroblastoma cells, enabling the immune system to recognize and eliminate these malignant cells. The drug is commonly administered as part of a comprehensive treatment approach that includes immunotherapy. Qarziba helps improve survival outcomes and lowers the likelihood of disease relapse in patients with neuroblastoma.

The primary indication types for Qarziba include high-risk neuroblastoma and relapsed or refractory neuroblastoma. High-risk neuroblastoma is an aggressive childhood cancer marked by the abnormal proliferation of nerve cells in areas such as the adrenal glands, neck, chest, abdomen, or pelvis, and is frequently diagnosed at advanced stages. Qarziba is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by end users including hospitals and specialized oncology clinics.

The qarziba market consists of sales of monoclonal antibody therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.